Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord which causes inflammation in the optic nerve and spinal cord.
Currently, the Neuromyelitis Optica Spectrum Disorder domain constitutes a robust pipeline with more than 20 drugs existing in the NMOSD therapeutic landscape, out of which 3 are marketed, and 17 are under different phases of development.
DelveInsight presents a new addition to its newsletter edition that focuses on the Neuromyelitis Optica Spectrum Disorder market. The newsletter offers a complete picture of the Neuromyelitis Optica Spectrum Disorder market landscape, pipeline therapies, ongoing clinical trials, as well as epidemiological insights, and current treatment therapies.
It also covers recent happenings in the Neuromyelitis Optica Spectrum Disorder market space, mergers and collaborations taking place, research & development, essential pharmaceutical companies involved in the Neuromyelitis Optica Spectrum Disorder market, licensing deals along with the details of top conferences expected to occur in the coming year.
Download our newsletter by filling up the form towards the right and stay informed about recent updates in the Neuromyelitis Optica Spectrum Disorder market.
Join our Newsletter series and get rich insights delivered every week to you.
Stay connected!
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Unmet needs
- Top conferences
- R&D in the field
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Neuromyelitis Optica Spectrum Disorder Market Dynamics
- Collaborations and deals in the domain
-Agonist.png)
